文献速递小儿骨科关节外科

18月龄后发育性髋关节脱位闭合复位与开放复位/Salter髂骨截骨术的比较:45年随访的生存率对比

Closed Vs. Open Reduction/Salter Innominate Osteotomy for Developmental Hip Dislocation After Age 18 Months: Comparative Survival at 45-Year Follow-up.
PubMed 文献 · J Bone Joint Surg Am · 2020-01-01

在18至60月龄的发育性髋关节脱位(DDH)患者中,比较闭合复位(CR)与开放复位联合Salter髂骨截骨术(OR/IO)后45年随访的全髋关节置换术(THA)风险与无THA生存时间;CR组THA风险高于OR/IO组,但未调整的无THA生存时间无差异;双侧病例中复位年龄较大者CR后THA风险更高。

要点

  • 在45年随访时,OR/IO组生存概率为0.63(95%CI 0.50-0.78),CR组为0.55(95%CI 0.43-0.72)。
  • 在双侧病例中,18月龄复位者CR后THA的HR为0.16(95%CI 0.04-0.64),36月龄复位者HR为4.23(95%CI 2.00-8.95)。
  • CR组和OR/IO组分别有17%和22%的髋关节需要额外手术。

核心结论

  • CR后发生骨关节炎和THA的可能性高于OR/IO,但数据未显示未调整的无THA生存时间存在差异。
  • 在双侧病例中,复位年龄较大与CR后THA风险高于OR/IO相关。
  • 两种治疗相对于DDH的自然病史均提供实质性获益,但THA是中年期的预期结局。

研究设计与样本

  • 回顾性比较研究,纳入18至60月龄的患者,45例(58髋)接受CR,58例(78髋)接受OR/IO,随访至少40年。
  • 生存分析中,若至48年未发生THA则删失;采用多变量Cox回归分析治疗、年龄和双侧受累对THA风险的影响。

主要发现

  • 在48年随访时,CR组29髋(50%)存活,OR/IO组54髋(69%)存活。
  • 在45年时,OR/IO组生存概率为0.63(95%CI 0.50-0.78),CR组为0.55(95%CI 0.43-0.72)。
  • 在单侧病例中,年龄和治疗对结局的影响极小;在双侧病例中,年龄显著改变治疗与结局的关系。
  • 在双侧组中,18月龄复位者CR后THA的预测HR为0.16(95%CI 0.04-0.64),36月龄复位者HR为4.23(95%CI 2.00-8.95)。
  • CR组17%的髋和OR/IO组22%的髋需要额外手术。

关键数值与推荐

  • 在45年随访时,OR/IO组无THA生存概率为0.63(95%CI 0.50-0.78),CR组为0.55(95%CI 0.43-0.72)。
  • 在双侧病例中,18月龄复位者CR后THA的HR为0.16(95%CI 0.04-0.64),36月龄复位者HR为4.23(95%CI 2.00-8.95)。
  • CR组额外手术率为17%,OR/IO组为22%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite widespread use of single-stage open reduction and pelvic osteotomy for treatment of developmental dysplasia of the hip (DDH) after walking age, this aggressive strategy remains controversial. We directly compared dislocated hips treated with closed reduction (CR) to those treated with open reduction and Salter innominate osteotomy (OR/IO) to estimate the relative hazard of total hip arthroplasty (THA) and the THA-free survival time. METHODS: In a series of patients 18 to 60 months of age, 45 patients (58 hips) underwent CR and 58 patients (78 hips) were treated with OR/IO and followed to a minimum 40 years post-reduction. Observations in the survival analysis were censored if no THA had occurred by 48 years. Multivariate Cox regression analysis was used to estimate the hazard of THA given treatment, age, and bilaterality. Complications and additional procedures were noted. RESULTS: At 48 years of follow-up, 29 (50%) of the hips survived after CR compared with 54 (69%) after OR/IO. At 45 years, the survival probability after OR/IO was 0.63 (95% confidence interval [CI] = 0.50 to 0.78) compared with 0.55 (95% CI = 0.43 to 0.72) after CR. The hazard ratio (HR) of THA was modeled as a function of treatment, age at reduction, and bilaterality. The effect of age and treatment on the outcome of hips in patients with unilateral involvement was minimal. However, age did significantly alter the relationship between treatment and outcome in bilateral cases. In the bilateral group, the predicted HR of THA was lower after CR in hips that were reduced at the age of 18 months (HR = 0.16, 95% CI = 0.04 to 0.64) but higher in those that were reduced at 36 months (HR = 4.23, 95% CI = 2.00 to 8.95). Additional procedures were indicated for 17% and 22% of hips after CR and OR/IO, respectively. CONCLUSIONS: Osteoarthritis and THA was more likely after CR than OR/IO, but the data do not indicate a difference in unadjusted hip-survival time. In patients with bilateral disease, an older age at reduction was associated with an increased hazard of THA after CR than after OR/IO. Both treatments provided substantial benefit relative to the natural history of DDH, but THA is the expected outcome in middle adulthood. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Scott EJ, Dolan LA, Weinstein SL, et al. Closed Vs. Open Reduction/Salter Innominate Osteotomy for Developmental Hip Dislocation After Age 18 Months: Comparative Survival at 45-Year Follow-up. J Bone Joint Surg Am. 2020. PMID: 32769602. doi:10.2106/JBJS.19.01278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。